To examine the association between the provision of professional pharmacy services (PPS) and patient complexity as determined by the number of distinct medications dispensed in Ontario. METHODS: We conducted a cross-sectional study among all individuals dispensed one or more medications under the Ontario Public Drug Program (OPDP) between April 1 st , 2012 and March 31 st , 2013. We compared characteristics of patients receiving 1 or more PPS to those receiving no PPS. To assess the relationship between patient complexity (as measured by the number of chronic medications dispensed) and receipt of PPS, we reported the number and proportion of patients eligible for Ontario Drug Benefits (ODB) who received a PPS within each patient complexity group, and compared these proportions using the CochranArmitage test. RESULTS: Over the 1-year study period, 27.1% (N = 799,674 of 2,946,183) of ODB beneficiaries received at least one professional pharmacy service. Among these services, more than two-thirds of the patients received a MedsCheck service (N=511,490; 64.0%). Overall, individuals who received a PPS tended to be older, more likely to reside in a long-term care (LTC) facility, have multiple comorbidities, and were more likely to have been prescribed 9 or more medications in the past year. As patient complexity increased, the proportion of ODB beneficiaries who received PPS also increased; 3.0% of individuals prescribed between 1 and 2 medications in the past year received PPS, while 53.6% of those treated with 13 or more medications received PPS (p<0.0001). CONCLUSIONS: Although the findings of our study suggest the use of PPS increases with patient complexity, many complex patients are not receiving these services. Further studies are required to better understand why patients do not access these services, the impact of professional pharmacy services on patient health outcomes, and their value for the health care system.
INTRODUCTION
Increasing scrutiny of health care budgets has pushed healthcare systems in several jurisdictions to expand the provision of services by allied health care professions. The expansion of professional pharmacy services (PPS) aims to better utilize the specialized knowledge of pharmacists to provide pharmaceutical patient care while increasing the efficiency of the healthcare system and improving patient outcomes. In particular, PPS aim to improve pharmaceutical care and address gaps in our system whereby medication errors occur. Many PPS focus on patients taking multiple medications, since polypharmacy predisposes patients to adverse drug reactions (1-3), drug-drug interactions (4, 5) and non-adherence (6,7).
The Ontario Public Drug Program initiated the MedsCheck Program in 2007 to address concerns around medication safety and polypharmacy. Ontarians taking 3 or more medications for a chronic condition are eligible for an annual one-on-_________________________________________ one meeting with their pharmacist to review their medications, better understand their medication therapy, and ensure that medications are being taken as prescribed (8 Program. Similar programs exist in other jurisdictions (9-11) and thus Ontario's experience is a case study in the implementation of these services.
Despite the introduction of targeted PPS over the past several years, little is known about the extent to which these services are used across Ontario, and whether they are being delivered to patients most at risk of adverse drug events. The objective of this study was to assess the extent to which patient complexity was related to provision of PPS in Ontario.
METHODS
We conducted a population-based cross-sectional study among all active ODB beneficiaries (defined as those who received one or more prescription drugs reimbursed by the 
Data Sources
We used the Ontario Drug Benefit (ODB) database to identify all patients eligible for public drug coverage, and all PPS provided over the study period. This database contains computerized records for all prescriptions and PPS reimbursed through the public drug program in Ontario, and has an error rate of less than 1% (12) . We identified patient demographics, including age, gender, income quintile and location of residence, using the Registered Persons Database, which contains information on all Ontarians who ever received a health card number. Finally, we used the Canadian Institute for Health Information (CIHI) Discharge Abstract Database, the CIHI National Ambulatory Care Reporting System, and the Ontario Health Insurance Program Database to identify patient history of inpatient hospitalizations, emergency department visits, and outpatient physician visits in the past 2 years, respectively.
Characteristics of Patients Receiving Professional Pharmacy Services
We identified all individuals who received at least one PPS over the study period and compared the characteristics of these patients to those eligible for public drug coverage who received no PPS over the same period. The index date for the cohort of patients receiving PPS was the date of the first service received over the study period. Among those receiving no PPS, the index date was defined as the date of their first medication received over the study period. Variables measured included age, sex, neighbourhood income quintile, location of residence (LTC or community), and rural or urban residence. Patient comorbidity was defined using the Johns Hopkins Aggregated Diagnostic Groups (ADGs) based on hospital visits, emergency department visits and physician claims in the 2 years prior to the index date. ADGs were used because these generate clinically similar clusters of patients based on recent diagnoses (13) . Furthermore, patient complexity was defined based on the number of distinct drugs dispensed to the patient in the past 1 year, categorized into 1-2, 3-4, 5-6, 7-8, 9-12 and 13 or more drugs (14) . We applied the number of distinct drugs used over a one-year period as a surrogate for patient complexity, which has shown to predict future physician visits, healthcare expenditures, mortality, and hospitalizations (14) .
Professional Pharmacy Services and Patient Complexity
To assess the relationship between increasing patient complexity and receipt of PPS, we reported the number and proportion of ODB eligible patients who received a PPS within each patient complexity group. In the analysis stratified by PPS type, patients who received multiple types of PPS over the year were included once in each PPS category.
STATISTICAL ANALYSIS
All binary variables were summarized using proportions, and continuous variables were summarized using medians and interquartile ranges (IQRs). We compared characteristics of patients who received PPS and those who did not using standardized differences. A standardized difference greater than 0.10 was defined as a meaningful difference (15) . We used the Cochran-Armitage trend test to determine whether there was a statistically significant increase in the prevalence of PPS by patient complexity. All analyses were conducted using SAS Version 9.3 (SAS Institute, Cary, North Carolina) at the Institute for Clinical Evaluative Sciences.
RESULTS
In fiscal year 2012, 27.1% (N = 799,674 of 2,946,183) of Ontarians eligible for public drug coverage received at least one PPS ( Table 1) . Among these services, two-thirds of the patients received a MedsCheck service (N=511,490), 15.4% (N=123,216) received a MedsCheck Diabetes service, 11.3% (N=90,288) received MedsCheck in LTC, 3.3% (N=26,529) received MedsCheck at home, and 22.3% (N=178,342) were part of the Pharmaceutical Opinion Program ( Table 2) . Only 0.5% (N=4,137) of patients were part of the Pharmacy Smoking Cessation Program.
Overall, individuals receiving PPS in Ontario were considerably different from those who received no services ( Table 1) . In particular, they tended to be older (median 73 years vs. 66 years) and more likely to reside in a LTC facility (10.9% vs. 0.3%). Furthermore, those receiving PPS were more likely to have multiple comorbidities (34.5% with 10 or more ADGs) compared to those who received no such services (19.8% with 10 or more ADGs), and were more likely to have been prescribed 13 or more medications in the past year (28.5% vs. 9.3% among PPS recipients and nonrecipients, respectively).
In general, we found that as patient complexity increased, the proportion of ODB beneficiaries who received PPS also increased (p<0.0001) (Figure 1) . For example, few individuals (3.0%) prescribed 1 to 2 medications in the past year received a PPS, while greater than half (53.6%) of those who received 13 or more medications received a PPS. Furthermore, the types of services provided became more variable as patient complexity increased (Figure 2 
DISCUSSION
This population-based study of PPS use in Ontario found that approximately one-third (27.1%) of patients eligible for public drug coverage received at least one service over the course of a year, and that the use of these services appears to increase as patient complexity increases. However, despite this trend, almost half of the most complex patients (those prescribed 13 or more prescriptions) did not receive any such services, suggesting that there is significant room for improvement of access and expansion to patients who could benefit from these services.
These low rates of PPS use are surprising given that 98% of pharmacies in Ontario provide MedsCheck services (8). Low observed rates may be driven by pharmacies infrequently offering these services. Many pharmacies may have limited staff and time to provide these services, or may be apprehensive to engage in new services that may interfere with workflow (16) . Furthermore, because pharmacy reimbursement for services is not tied to patient complexity, some pharmacists may be deterred from providing these services to highly complex patients taking multiple medications given the time commitment required to conduct the service (17) . The introduction of new PPS in Alberta and Saskatchewan revealed varying levels of acceptability from pharmacists based on factors including the perception of the ability of services to improve patient care, easy incorporation into workflow, ability to provide adequate follow-up and liability (18, 19) . Additionally, patient compliance and refusal of service may be partially driving these results. Studies in other jurisdictions have shown that following the implementation of similar services, patient refusal of these services steadily declined over time (21, 22) . In addition to increased uptake, patient perceptions of PPS in other jurisdictions have considerably improved over time in the areas of medications reviews (22) and with pharmacists as immunizers (23) (24) (25) (26) . At the time of this study all programs were still relatively new and uptake of services is likely to rise with increased familiarity.
Complex patients are among the most vulnerable subjects, as well as being a group that consumes a great amount of healthcare resources. As a result, several programs exist that have been designed to target pharmacy services towards these high needs patients. For example, Fairview Pharmacy Service's Medication Therapy Management (MTM) Program in the United States uses internal databases to identify complex patients using criteria that include individuals not meeting their goals of therapy, those missing key drug therapies, and those with high utilization patterns and risk (27) . Studies analyzing the effect of Fairview Pharmacy's MTM services targeting diabetes and asthma management have demonstrated statistically significant improvements in clinical parameters for both groups (27, 28) . Furthermore, in a randomized controlled trial conducted in Ontario, Hogg et al. showed that in a study randomizing 'at-risk' patients to either standard care or to an interdisciplinary team, which included the use of PPS provided by a pharmacist, the team care approach led to improved quality of care for chronic disease management (29) . Although other jurisdictions across Canada and internationally have implemented PPS, we are unable to compare the uptake of services in Ontario to that of other jurisdictions since there is a paucity of evidence related to this topic, particularly those which compare service uptake by patient complexity. This highlights the need for further research in this area, which will allow for comparisons between jurisdictions that can inform policy-makers as they continue to develop and review these services.
Our study has several strengths, including the population-based nature of the analysis, and the ability to look at associations between receipt of PPS in regular practice and patient complexity and comorbidity. However, some limitations merit emphasis. First, our definition of PPS is based on specific services for which pharmacists can bill for reimbursement. It is possible that some pharmacists are providing these services to patients without billing for reimbursement, which we would not capture. However, given that these services are readily reimbursed, it is unlikely to have a large influence on our findings. Second, we restricted our population to those individuals who are eligible for public drug coverage in Ontario to ensure that we could determine their past medication history. Since all individuals aged 65 and older in Ontario are eligible for drug coverage, we estimate that this cohort captures a large proportion of complex patients.
CONCLUSION
Although the prevalence of use of PPS in Ontario is fairly high, there remain a large number of underserviced patients with complex medical needs who may benefit from these programs. Future research is required to better understand the facilitators and barriers to access of PPS among complex patients and, ultimately, the impact of PPS on patient health outcomes. 
